Rep. Lizzie Fletcher Sells Eli Lilly and Company (NYSE:LLY) Stock

Representative Lizzie Fletcher (Democratic-Texas) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 01st, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on April 8th. The trade occurred in the Representative’s “FILER BROKERAGE ACCOUNT (CB)” account.

Representative Lizzie Fletcher also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of KLA (NASDAQ:KLAC) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of Quanta Services (NYSE:PWR) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of Ameriprise Financial (NYSE:AMP) on 4/8/2026.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 4/8/2026.

Eli Lilly and Company Trading Up 3.3%

NYSE LLY opened at $965.19 on Friday. The firm’s 50 day moving average price is $947.05 and its two-hundred day moving average price is $984.98. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a market cap of $911.93 billion, a price-to-earnings ratio of 42.06, a PEG ratio of 1.10 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 115.33% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 33.79 EPS for the current year.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Royal Bank Of Canada started coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price target for the company. Finally, Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,218.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares in the last quarter. State Street Corp grew its position in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after acquiring an additional 635,358 shares in the last quarter. Capital Research Global Investors grew its position in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. Morgan Stanley increased its stake in shares of Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares during the last quarter. Finally, Capital World Investors increased its stake in shares of Eli Lilly and Company by 0.4% during the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly’s Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

About Representative Fletcher

Lizzie Pannill Fletcher (Democratic Party) is a member of the U.S. House, representing Texas’ 7th Congressional District. She assumed office on January 3, 2019. Her current term ends on January 3, 2027.

Fletcher (Democratic Party) ran for re-election to the U.S. House to represent Texas’ 7th Congressional District. She won in the general election on November 5, 2024.

Lizzie Pannill Fletcher was born and lives in Houston, Texas. She graduated from St. John’s School. She earned a bachelor’s degree in history from Kenyon College and a J.D. from William & Mary Law School. Fletcher’s career experience includes working as a lawyer. She co-founded Planned Parenthood Young Leaders in 2000. Fletcher serves as a board member of Writers in the Schools and Open Dance Project.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.